Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy

NCT07310186 | Not Yet Recruiting DMC

• 1 other identifier: PUMCH-NHL-022
• Study Type: observational
• Target: 200
• Locations: 0 countries
• Sites: N/A

Brief Summary

Diffuse Large B-cell Lymphoma (DLBCL) is a common hematologic malignancy. Even after standard first-line treatment, approximately 40% of patients will experience relapse. Currently, polatuzumab vedotin (pola) has been incorporated into DLBCL treatment (both for newly diagnosed and relapsed cases). However, for patients whose disease progresses after pola-containing regimens, the subsequent treatment options, efficacy, and survival outcomes remain unclear. Understanding these real-world scenarios is of great significance, as it can guide clinicians in developing better and more tailored treatment strategies for patients in the future. Therefore, we plan to conduct this real-world study titled "Salvage Treatment Strategies and Clinical Outcomes in Diffuse Large B-cell Lymphoma After Failure of Polatuzumab Vedotin-based Combination Therapy", aiming to obtain real-world data from the Chinese population.

Conditions

Diffuse Large B Cell Lymphoma (DLBCL)

Keywords

DLBCL; polatuzumab vedotin; Salvage Treatment

Outcome Measures

Primary Outcomes (1)

• complete response rate

  the ratio of patients achieves complete response

  through study completion, an average of 2 years

Interventions

observational study OTHER

this is an observational study, we do not interfere with treatment strategies

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

200

You may qualify if:

• Patients diagnosed with DLBCL
• Age ≥18 years
• Prior treatment with a polatuzumab vedotin (pola)-containing regimen and confirmed disease progression (refractory/relapsed) after this therapy.
• Availability of complete electronic medical records and ability to be contacted via telephone.
• Full understanding of the study, voluntary participation, and willingness to sign the informed consent form.

You may not qualify if:

• Patients who have not received pola-based regimen treatment.
• Incomplete electronic medical records or unreachable by telephone.

Sponsors & Collaborators

• Peking Union Medical College Hospital: lead

MeSH Terms

Conditions

Lymphoma, Large B-Cell, Diffuse

Interventions

Observation

Condition Hierarchy (Ancestors)

Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Intervention Hierarchy (Ancestors)

Methods; Investigative Techniques

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Target Duration: 2 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 22, 2025
• First Posted: December 30, 2025
• Study Start: December 30, 2025
• Primary Completion (Estimated): December 30, 2026
• Study Completion (Estimated): December 30, 2027
• Last Updated: December 30, 2025

Record last verified: 2025-07